Cingulate Names Chief Commercial Officer, Gains $6M for ADHD Drug

Cingulate has named industry veteran Bryan Downey as its new chief commercial officer. Photo credit: Shutterstock (alicancomertpay).

Posted November 12, 2025

Biopharmaceutical company Cingulate Inc. announced it has hired Bryan Downey as chief commercial officer.

Following the U.S. Food and Drug Administration’s decision to accept Cingulate’s new drug application, the company announced the appointment of Bryan Downey as the new CCO, according to a release.

Downey brings more than 25 years of experience in commercial strategy to the company. Before joining Cingulate, he most recently served as the managing director in CRA | Admired Leadership’s Leadership Advisory Practice in New York.

He held senior executive roles at Alfasigma USA and Jubilant Pharma, where he led commercial operations and product commercialization. He also served at Sanofi for more than 17.5 years, where he held the position of vice president and head of the U.S. cardiovascular and allergy business unit, overseeing product launches and brand strategies.

Cingulate also announced the completion of a $6 million financing transaction as it prepares for the commercialization of its new drug. Cingulate entered the transaction deal with Utah-based Avondale Capital, LLC, according to a Securities and Exchange Commission Form 8-K.

In October, the U.S. Food and Drug Administration accepted Cingulate’s new drug application for CTx-1301, a precision time-released drug for ADHD that allows for a once-daily dose as opposed to other multi-dose treatments. The FDA still has until May 31 to decide whether to grant CTx-1301 commercialization approval.

“His [Downey’s] experience driving successful product launches and organizational growth will be instrumental as we execute a disciplined, capital-efficient strategy to bring CTx-1301 to market, pending FDA approval,” Cingulate Executive Chairman Jay Roberts said in the release. “In parallel, this latest financing meaningfully extends our cash runway, providing the resources needed to advance launch readiness activities and position Cingulate for a successful commercialization phase.”